Developer docs
API playgroundTry for free, no card

Search company profiles

RepliCel Life Sciences

Full company profile

uuid0006g1e

Namestring
RepliCel Life Sciences
Legal namestring
RepliCel Life Sciences Inc.
Websiteurl
replicel.com
Company typeenum
Public
Founded yearint
2011
Descriptiontext

RepliCel Life Sciences is a clinical-stage regenerative medicine company headquartered in Vancouver, Canada, founded in 2011. It develops autologous cell therapies derived from cells isolated from a patient's own hair follicles, applied across three indications: RCH-01 for androgenetic alopecia (pattern hair loss), RCS-01 for aging and sun-damaged skin rejuvenation, and RCT-01 for chronic tendon degeneration such as Achilles tendinopathy. The underlying technology leverages dermal sheath cup (DSC) cells and non-bulbar dermal sheath (NBDS) cells, with proprietary cryopreservation protocols enabling long-term storage and distribution. In parallel, the company has developed DermaPrecise™ (RCI-02), a motorized dermal injection device with programmable depth, volume, and flow-rate control, a Peltier cooling element for pre-injection numbing, and interchangeable needle head configurations.

The company operates an asset-light, partnership-driven business model. RepliCel does not sell products directly; instead it has licensed exclusive regional commercial rights to its cell therapies and device. Shiseido Company holds exclusive co-development and commercialization rights for RCH-01 in Asia (including Japan), funding clinical trials, manufacturing, regulatory approvals, and sales/marketing there, with RepliCel entitled to upfront fees, milestones, and 10-year post-launch sales royalties. YOFOTO (China) Health Company holds exclusive rights for RCT-01 and RCS-01 in Greater China and for DermaPrecise™ in Greater China dermatology applications, co-funding program development. RepliCel retains all rights outside Asia and Greater China.

As of February 2025, RepliCel has no commercially launched products and no disclosed operating revenue. The company completed an asset sale and royalty transaction in February 2025 and announced voluntary delisting from the TSX Venture Exchange on February 21, 2025, with the public entity shell renamed RepliCel Life Sciences Inc. on March 3, 2025. Headcount is 11-50 employees. Clinical milestones to date include a completed Phase 2 dose-finding study for RCH-01 in Japan (65 patients) showing statistically significant increases in hair density and diameter, zero serious adverse events in Phase 1 and Phase 2 trials, and peer-reviewed publications in dermatology and sports medicine journals.

Short descriptiontext

RepliCel Life Sciences is a clinical-stage Canadian regenerative medicine company developing autologous cell therapies (RCH-01, RCS-01, RCT-01) and the DermaPrecise™ motorized injector, targeting pattern hair loss, skin rejuvenation, and chronic tendinopathy, commercialized via exclusive regional licenses with Shiseido and YOFOTO.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy products, regenerative medicine, autologous cell therapy, medical injection devices, tissue repair therapies
Industry3 codes
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Regenerative Medicine (Cell Therapy and Medical Device)
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing Royalties (Shiseido)
TypeLicensing Royalties
Description

Shiseido pays upfront licensing fees, post-commercial milestone payments, and sales royalties (for 10 years after launch) for RCH-01 commercialization in Asia. Shiseido funds all clinical testing, regulatory approvals, manufacturing, sales and marketing in Asia.

2Licensing Royalties (YOFOTO)
TypeLicensing Royalties
Description

YOFOTO holds exclusive license for RCT-01 and RCS-01 in Greater China and RCI-02 device in Greater China for dermatology. Partnership involves co-development with YOFOTO funding programs in Greater China.

3Product Sales (Future)
TypeOne Time License
Description

Pre-commercial stage. Asset sale and royalty transaction completed in February 2025. Company is delisting from TSX Venture Exchange as it transitions to private/public delisted status.

replicel.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1DermaPrecise™
Description

Next-generation dermal injection technology - a motorized injection device with programmable depth and volume, built-in Peltier element for pre-injection numbing, and interchangeable needle head configurations.

replicel.com
+3 more records
Core offering1 text field

RepliCel Life Sciences develops and licenses autologous cell therapy products (RCH-01 for androgenetic alopecia, RCS-01 for skin rejuvenation, and RCT-01 for chronic Achilles tendinopathy) derived from cells isolated from the patient's own hair follicles. The company also developed DermaPrecise™ (RCI-02), a next-generation motorized dermal injection device with programmable depth and volume control for delivering injectable substances into the dermis and subcutaneous tissue.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 5-13 more hairs per square centimeter at 9 months post-treatment in best responders
+2 more records
Product overview1 text field

RepliCel Life Sciences is a regenerative medicine company developing a portfolio of autologous cell therapies and a medical device. The company has three cell therapy products: RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair growth—all derived from cells isolated from the patient's own hair follicles. The DermaPrecise™ (RCI-02) dermal injector device is designed to improve the delivery of these cell therapies and other injectable substances. The products work together as the company develops cell-based treatments while also creating an optimized injection device to administer them.

Product and service4 records
1RCH-01 Hair Growth
CategoryCell Therapy Product
Description

Autologous cell therapy using dermal sheath cup (DSC) cells isolated from the patient's own hair follicles to regenerate hair in balding areas of the scalp and treat androgenetic alopecia (male and female pattern hair loss). Licensed exclusively to Shiseido Company for Asia.

2RCS-01 Skin Rejuvenation
CategoryCell Therapy Product
Description

Autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells to repair and regenerate aging and sun-damaged skin tissue by generating new collagen (Type 1 and Type 2) and elastin under the skin. Licensed exclusively to YOFOTO for Greater China.

3RCT-01 Tendon Repair
CategoryCell Therapy Product
Description

Autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells isolated from hair follicles to repair degenerated tendon tissue in patients with chronic Achilles tendinopathy, with the goal of regenerating tendon tissue, restoring blood flow, decreasing pain, and increasing function. Licensed exclusively to YOFOTO for Greater China.

4DermaPrecise™ (RCI-02) Motorized Injector
CategoryMedical Device Product
Description

Next-generation motorized dermal injection device with programmable depth, volume, flow rate, and shear stress; integrated Peltier element for pre-injection numbing; and interchangeable needle head configurations from a single needle up to a 16-needle 4x4 array, controlled via touch-screen docking station for 3-dimensional deposition of injectable substances (hyaluronic acid fillers, toxins, fat, collagen) into dermis and subcutaneous tissue.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Shiseido Company
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

Shiseido licensed exclusive co-development and commercial rights for RCH-01 hair growth product in Asia. The agreement involved upfront licensing fee, post-commercial milestone payments, and sales royalties (10 years after launch). Shiseido funds all clinical testing, regulatory approvals, manufacturing, sales and marketing in Asia. RepliCel conducted extensive technology transfer of all production and quality control aspects and supported facility design, validation, and personnel training at Shiseido's Kobe, Japan manufacturing facility.

2YOFOTO (China) Health Company
Strategic tierCoreTypeStrategic or Co-development Partner
Description

YOFOTO holds exclusive license for RCT-01 tendon repair and RCS-01 skin rejuvenation in Greater China. YOFOTO also has exclusive commercial rights for RCI-02 DermaPrecise™ device in Greater China for dermatology applications. YOFOTO is funding programs in Greater China and expected to first launch the device in Hong Kong upon CE mark approval. Transaction involves financing RepliCel's programs in Greater China.

3Tokyo Medical University Hospital
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Conducted Phase 2 clinical trial for RCH-01 hair growth product as part of Shiseido-funded study. Study involved 65 patients (50 males, 15 females) with pattern hair loss.

4Toho University Ohasi Medical Center
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Conducted Phase 2 clinical trial for RCH-01 hair growth product as part of Shiseido-funded study. Study confirmed safety and efficacy of autologous cell-based therapy using dermal sheath cup cells.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developed autologous fibroblast cell therapy (azficel-T/laViv) for skin aesthetics and is pursuing cell and gene therapies for dermatology indications. Directly comparable business model and autologous cell-therapy approach for cosmetic dermatology.

TypeDirect peer
Description

Pursued regenerative cell-conditioned media and cell therapy approaches for androgenetic alopecia and hair restoration. Most direct competitor to RCH-01 in the autologous/allogeneic hair regeneration category.

TypeDirect peer
Description

Japanese company specializing in cell-based hair multiplication therapy (Ji JAMI) using autologous hair follicle cells. Direct peer in autologous cell therapy for androgenetic alopecia; later acquired by Shiseido, RepliCel's RCH-01 partner.

TypeDirect peer
Description

Japan-based regenerative medicine company developing autologous cell-based treatments for hair loss using follicle-derived cells. Highly comparable technology and target indication (androgenetic alopecia).

TypeEmerging player
Description

Pre-clinical company using iPSC-derived cells to engineer new hair follicles for androgenetic alopecia. Emerging player targeting the same patient population as RCH-01 with a different cell source.

TypeEmerging player
Description

Developed a regenerative hair growth procedure combining skin disruption with a topical compound to create new hair follicles. Adjacent technology targeting the same androgenetic alopecia indication via a dermatology-office procedure.

TypeEmerging player
Description

Regenerative medicine company developing autologous cell-based skin and tissue regeneration products (e.g., SkinTE). Direct peer in autologous tissue regeneration for dermatology applications.

TypeDirect peer
Description

Develops autologous cell therapies including MACI for cartilage repair and Epicel for severe burns. Direct peer in autologous cell therapy for musculoskeletal/tissue indications analogous to RCT-01.

TypeBroad incumbent
Description

Commercial-stage regenerative medicine company with cell therapies targeting inflammatory conditions and orthopedic/tissue repair. Broader incumbent in autologous/allogeneic cell therapy for musculoskeletal indications.

10Shiseido Company
TypeBroad incumbent
Description

Holds exclusive Asian rights to RCH-01 and acquired Aderans; large beauty/pharmaceutical incumbent with significant dermatology and regenerative medicine exposure. Comparable as a partner in RepliCel's commercialization model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RepliCel Life Sciences

Regenerative Medicine (Cell Therapy and Medical Device)replicel.com

RepliCel Life Sciences is a clinical-stage Canadian regenerative medicine company developing autologous cell therapies (RCH-01, RCS-01, RCT-01) and the DermaPrecise™ motorized injector, targeting pattern hair loss, skin rejuvenation, and chronic tendinopathy, commercialized via exclusive regional licenses with Shiseido and YOFOTO.

What RepliCel Life Sciences does

RepliCel Life Sciences is a clinical-stage regenerative medicine company headquartered in Vancouver, Canada, founded in 2011. It develops autologous cell therapies derived from cells isolated from a patient's own hair follicles, applied across three indications: RCH-01 for androgenetic alopecia (pattern hair loss), RCS-01 for aging and sun-damaged skin rejuvenation, and RCT-01 for chronic tendon degeneration such as Achilles tendinopathy. The underlying technology leverages dermal sheath cup (DSC) cells and non-bulbar dermal sheath (NBDS) cells, with proprietary cryopreservation protocols enabling long-term storage and distribution. In parallel, the company has developed DermaPrecise™ (RCI-02), a motorized dermal injection device with programmable depth, volume, and flow-rate control, a Peltier cooling element for pre-injection numbing, and interchangeable needle head configurations.

The company operates an asset-light, partnership-driven business model. RepliCel does not sell products directly; instead it has licensed exclusive regional commercial rights to its cell therapies and device. Shiseido Company holds exclusive co-development and commercialization rights for RCH-01 in Asia (including Japan), funding clinical trials, manufacturing, regulatory approvals, and sales/marketing there, with RepliCel entitled to upfront fees, milestones, and 10-year post-launch sales royalties. YOFOTO (China) Health Company holds exclusive rights for RCT-01 and RCS-01 in Greater China and for DermaPrecise™ in Greater China dermatology applications, co-funding program development. RepliCel retains all rights outside Asia and Greater China.

As of February 2025, RepliCel has no commercially launched products and no disclosed operating revenue. The company completed an asset sale and royalty transaction in February 2025 and announced voluntary delisting from the TSX Venture Exchange on February 21, 2025, with the public entity shell renamed RepliCel Life Sciences Inc. on March 3, 2025. Headcount is 11-50 employees. Clinical milestones to date include a completed Phase 2 dose-finding study for RCH-01 in Japan (65 patients) showing statistically significant increases in hair density and diameter, zero serious adverse events in Phase 1 and Phase 2 trials, and peer-reviewed publications in dermatology and sports medicine journals.

RepliCel Life Sciences firmographics

Firmographics
Name
RepliCel Life Sciences
Legal name
RepliCel Life Sciences Inc.
Website
https://replicel.com
Company type
Public
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Short description
RepliCel Life Sciences is a clinical-stage Canadian regenerative medicine company developing autologous cell therapies (RCH-01, RCS-01, RCT-01) and the DermaPrecise™ motorized injector, targeting pattern hair loss, skin rejuvenation, and chronic tendinopathy, commercialized via exclusive regional licenses with Shiseido and YOFOTO.
Ownership category
akta.pro rank

RepliCel Life Sciences industry classification

Industry
Product category
Regenerative Medicine (Cell Therapy and Medical Device)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Biological Products, (No Disgnostic Substances) (2836), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Cell therapy products
  • Regenerative medicine
  • Autologous cell therapy
  • Medical injection devices
  • Tissue repair therapies

Where RepliCel Life Sciences is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

RepliCel Life Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Licensing Royalties (Shiseido): Shiseido pays upfront licensing fees, post-commercial milestone payments, and sales royalties (for 10 years after launch) for RCH-01 commercialization in Asia. Shiseido funds all clinical testing, regulatory approvals, manufacturing, sales and marketing in Asia.
  2. Licensing Royalties (YOFOTO): YOFOTO holds exclusive license for RCT-01 and RCS-01 in Greater China and RCI-02 device in Greater China for dermatology. Partnership involves co-development with YOFOTO funding programs in Greater China.
  3. Product Sales (Future): Pre-commercial stage. Asset sale and royalty transaction completed in February 2025. Company is delisting from TSX Venture Exchange as it transitions to private/public delisted status.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

RepliCel Life Sciences product offering

Product offering

Core offering

RepliCel Life Sciences develops and licenses autologous cell therapy products (RCH-01 for androgenetic alopecia, RCS-01 for skin rejuvenation, and RCT-01 for chronic Achilles tendinopathy) derived from cells isolated from the patient's own hair follicles. The company also developed DermaPrecise™ (RCI-02), a next-generation motorized dermal injection device with programmable depth and volume control for delivering injectable substances into the dermis and subcutaneous tissue.

Product overview

RepliCel Life Sciences is a regenerative medicine company developing a portfolio of autologous cell therapies and a medical device. The company has three cell therapy products: RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair growth—all derived from cells isolated from the patient's own hair follicles. The DermaPrecise™ (RCI-02) dermal injector device is designed to improve the delivery of these cell therapies and other injectable substances. The products work together as the company develops cell-based treatments while also creating an optimized injection device to administer them.

Differentiator

Problem solved

Functional benefit

Brands

  • DermaPrecise™: Next-generation dermal injection technology - a motorized injection device with programmable depth and volume, built-in Peltier element for pre-injection numbing, and interchangeable needle head configurations.
  • RCH-01
  • RCS-01
  • RCT-01

Products and services

  • RCH-01 Hair Growth Autologous cell therapy using dermal sheath cup (DSC) cells isolated from the patient's own hair follicles to regenerate hair in balding areas of the scalp and treat androgenetic alopecia (male and female pattern hair loss). Licensed exclusively to Shiseido Company for Asia.
  • RCS-01 Skin Rejuvenation Autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells to repair and regenerate aging and sun-damaged skin tissue by generating new collagen (Type 1 and Type 2) and elastin under the skin. Licensed exclusively to YOFOTO for Greater China.
  • RCT-01 Tendon Repair Autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells isolated from hair follicles to repair degenerated tendon tissue in patients with chronic Achilles tendinopathy, with the goal of regenerating tendon tissue, restoring blood flow, decreasing pain, and increasing function. Licensed exclusively to YOFOTO for Greater China.
  • DermaPrecise™ (RCI-02) Motorized Injector Next-generation motorized dermal injection device with programmable depth, volume, flow rate, and shear stress; integrated Peltier element for pre-injection numbing; and interchangeable needle head configurations from a single needle up to a 16-needle 4x4 array, controlled via touch-screen docking station for 3-dimensional deposition of injectable substances (hyaluronic acid fillers, toxins, fat, collagen) into dermis and subcutaneous tissue.

Quantifiable outcome

  • 5-13 more hairs per square centimeter at 9 months post-treatment in best responders
  • +2 more outcomes

Companies that use RepliCel Life Sciences

Customer profile

Segments4 records

Ideal customer profiles3 records

RepliCel Life Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

RepliCel Life Sciences partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Shiseido CompanycoreStrategic or Co-development Partner · 1 January 2016Shiseido licensed exclusive co-development and commercial rights for RCH-01 hair growth product in Asia. The agreement involved upfront licensing fee, post-commercial milestone payments, and sales royalties (10 years after launch). Shiseido funds all clinical testing, regulatory approvals, manufacturing, sales and marketing in Asia. RepliCel conducted extensive technology transfer of all production and quality control aspects and supported facility design, validation, and personnel training at Shiseido's Kobe, Japan manufacturing facility.
  • YOFOTO (China) Health CompanycoreStrategic or Co-development PartnerYOFOTO holds exclusive license for RCT-01 tendon repair and RCS-01 skin rejuvenation in Greater China. YOFOTO also has exclusive commercial rights for RCI-02 DermaPrecise™ device in Greater China for dermatology applications. YOFOTO is funding programs in Greater China and expected to first launch the device in Hong Kong upon CE mark approval. Transaction involves financing RepliCel's programs in Greater China.
  • Tokyo Medical University HospitalminorStrategic or Co-development PartnerConducted Phase 2 clinical trial for RCH-01 hair growth product as part of Shiseido-funded study. Study involved 65 patients (50 males, 15 females) with pattern hair loss.
  • Toho University Ohasi Medical CenterminorStrategic or Co-development PartnerConducted Phase 2 clinical trial for RCH-01 hair growth product as part of Shiseido-funded study. Study confirmed safety and efficacy of autologous cell-based therapy using dermal sheath cup cells.

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

RepliCel Life Sciences competitors and assessment

Company assessment

Direct peers

  • Castle Creek Biosciences (formerly Fibrocell Science): Developed autologous fibroblast cell therapy (azficel-T/laViv) for skin aesthetics and is pursuing cell and gene therapies for dermatology indications. Directly comparable business model and autologous cell-therapy approach for cosmetic dermatology.
  • Histogen (now Kerastem): Pursued regenerative cell-conditioned media and cell therapy approaches for androgenetic alopecia and hair restoration. Most direct competitor to RCH-01 in the autologous/allogeneic hair regeneration category.
  • Aderans Company: Japanese company specializing in cell-based hair multiplication therapy (Ji JAMI) using autologous hair follicle cells. Direct peer in autologous cell therapy for androgenetic alopecia; later acquired by Shiseido, RepliCel's RCH-01 partner.
  • Rion (Rion Co., Ltd.): Japan-based regenerative medicine company developing autologous cell-based treatments for hair loss using follicle-derived cells. Highly comparable technology and target indication (androgenetic alopecia).
  • Vericel (formerly Aastrom Biosciences): Develops autologous cell therapies including MACI for cartilage repair and Epicel for severe burns. Direct peer in autologous cell therapy for musculoskeletal/tissue indications analogous to RCT-01.

Emerging players

  • Stemson Therapeutics: Pre-clinical company using iPSC-derived cells to engineer new hair follicles for androgenetic alopecia. Emerging player targeting the same patient population as RCH-01 with a different cell source.
  • Follica: Developed a regenerative hair growth procedure combining skin disruption with a topical compound to create new hair follicles. Adjacent technology targeting the same androgenetic alopecia indication via a dermatology-office procedure.
  • PolarityTE: Regenerative medicine company developing autologous cell-based skin and tissue regeneration products (e.g., SkinTE). Direct peer in autologous tissue regeneration for dermatology applications.

Broad incumbents

  • Mesoblast: Commercial-stage regenerative medicine company with cell therapies targeting inflammatory conditions and orthopedic/tissue repair. Broader incumbent in autologous/allogeneic cell therapy for musculoskeletal indications.
  • Shiseido Company: Holds exclusive Asian rights to RCH-01 and acquired Aderans; large beauty/pharmaceutical incumbent with significant dermatology and regenerative medicine exposure. Comparable as a partner in RepliCel's commercialization model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

RepliCel Life Sciences social profiles

Digital presence

RepliCel Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RepliCel Life Sciences leadership team

Management profile

Number of profiles

Profiles6 records

RepliCel Life Sciences funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RepliCel Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RepliCel Life Sciences

What does RepliCel Life Sciences do?

RepliCel Life Sciences develops and licenses autologous cell therapy products (RCH-01 for androgenetic alopecia, RCS-01 for skin rejuvenation, and RCT-01 for chronic Achilles tendinopathy) derived from cells isolated from the patient's own hair follicles. The company also developed DermaPrecise™ (RCI-02), a next-generation motorized dermal injection device with programmable depth and volume control for delivering injectable substances into the dermis and subcutaneous tissue.

Is RepliCel Life Sciences a public or private company?

RepliCel Life Sciences is a public company. It is classified as public and is currently operating.

When was RepliCel Life Sciences founded?

RepliCel Life Sciences was founded in 2011. It employs 1 to 10 people.

Where is RepliCel Life Sciences based?

RepliCel Life Sciences is headquartered in Vancouver, Canada, in the North America region.

How does RepliCel Life Sciences make money?

Three revenue lines are on record. Licensing Royalties (Shiseido) is the primary driver. The others are licensing Royalties (YOFOTO) and product Sales (Future).

Who are RepliCel Life Sciences's main competitors?

Direct peers on record are Castle Creek Biosciences (formerly Fibrocell Science), Histogen (now Kerastem), Aderans Company, Rion (Rion Co., Ltd.) and Vericel (formerly Aastrom Biosciences). Emerging players are Stemson Therapeutics, Follica and PolarityTE. Broad incumbents are Mesoblast and Shiseido Company.

Does RepliCel Life Sciences have an API?

No public API is recorded for RepliCel Life Sciences.

What industry is RepliCel Life Sciences in?

RepliCel Life Sciences's product category is Regenerative Medicine (Cell Therapy and Medical Device). Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceRepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation TestingRepliCel Life Sciences shipped DermaPrecise injector prototypes and consumables to Monasterium Laboratory in Germany for validation studies on injection parameters using donated human skin tissue. The independent testing will assess depth and biodistribution of injected substances via histological and imaging analysis.BioSpaceRepliCel Announces DermaPrecise Trademark for Dermal Injector Product LineRepliCel Life Sciences announced the DermaPrecise trademark for its dermal injector product line. The electronic injector offers precision control over injection depth and dose, with applications for cell and gene therapies, dermal fillers, and aesthetic procedures. The company plans to publish data on its superiority and pursue regulatory approvals in the US, Europe, Hong Kong, and Japan.PR NewswireRepliCel Announces its Incoming Board of DirectorsRepliCel Life Sciences Inc. held its annual general meeting on December 18, 2019, where shareholders elected six directors to its board and the company announced the appointment of Zhan (Gavin) Ye as a new board member. The new director brings cross-border experience between Canada and Asian markets including Hong Kong, China, Singapore, South Korea, and Taiwan, which the company expects to support its international expansion strategy. RepliCel's strategic partners, including YOFOTO (China) Health Company and Shiseido Company, are currently co-developing cell therapy products in Greater China and Japan respectively.PR NewswireClinical Data Published from RepliCel's Skin Rejuvenation StudyRepliCel Life Sciences announced the publication of clinical data from its RCS-01 skin rejuvenation Phase I trial in the peer-reviewed journal Skin Pharmacology and Physiology. The study demonstrated that RCS-01 injections are safe and well-tolerated for up to one year post-injection, with results showing the treatment altered gene expression profiles related to extracellular matrix homeostasis, suggesting potential for reversing skin aging effects.PR NewswireRepliCel Life Sciences Retains Dermatology Sales and Marketing Executive to Guide the Global Commercial Strategy for its Automated Dermal InjectorRepliCel Life Sciences announced the retention of Damien King to help develop its global commercial strategy for its upcoming dermal injector product line. The product is expected to be launched in Europe and Hong Kong next year after receiving marketing approval. The company is preparing for product manufacturing, testing, and regulatory approval.PR NewswireRepliCel Secures Several New Patents for its Regenerative Medicine TechnologiesRepliCel Life Sciences Inc. announced the receipt of patent grants and allowances for its regenerative medicine technologies across multiple jurisdictions including Europe, China, Hong Kong, Japan, the United States, South Africa, and Russia. The patents cover three technology families: tendon regeneration using non-bulbar dermal sheath cup cell technology, a dermal injection device expected to launch in Europe next year with CE Mark approval, and skin rejuvenation treatments. The company is co-developing its tendon repair and skin rejuvenation products with partner YOFOTO for Greater China while separately advancing a hair restoration product with Shiseido in Japan.PR NewswireRepliCel's Licensee Building Momentum in China with Facility and TeamRepliCel Life Sciences licensee YOFOTO (China) Health has initiated facility construction in Ningbo and hired staff to prepare for clinical trials of its cell therapy products in China. The company aims to submit initial regulatory documentation by mid-2019 to commence trials for RCS-01 and RCT-01, while also planning to launch the RCI-02 injector device in Hong Kong upon receiving CE mark approval.PR NewswireRepliCel Reignites its First-in-Japan StrategyRepliCel Life Sciences has resumed its First-in-Japan strategy, working with CJ PARTNERS to conduct next-phase clinical trials for its cell therapy products in Japan, where a single approved trial can potentially lead to market launch. The company anticipates launching all four products in its portfolio in Japan by 2022, including RCH-01 for hair loss (licensed to Shiseido), RCT-01 for tendinopathy, and RCS-01 for skin rejuvenation. The regulatory reforms in Japan for regenerative medicine are creating opportunities for foreign companies to sponsor their own clinical development and bring products to market faster than in other regions.PR NewswireRepliCel CEO Provides 2019 Shareholder UpdateRepliCel Life Sciences Inc. announced a new three-part strategic plan focused on transitioning to commercial revenue, including prioritizing CE mark approval and launch of its RCI-02 dermal injector by mid-2020, continuing clinical development of tendon and skin products in Japan, and supporting partnership commitments with YOFOTO in China and Shiseido in Asia. The company also disclosed that its disagreement with Shiseido regarding the licensing agreement for RCH-01 remains unresolved, though no litigation is pending, and revealed that new European regulations have impacted commercialization timelines.PR NewswireRepliCel Life Sciences Appoints Head of Clinical and Regulatory AffairsRepliCel Life Sciences Inc. announced the appointment of Dr. Petra Goessens-Rueck as Head of Clinical and Regulatory Affairs, formalizing her role after serving as a consultant to the company since its inception. Dr. Goessens-Rueck brings over 10 years of experience in cellular therapeutics development and will oversee clinical trial execution and regulatory submissions. The appointment strengthens the company's management team and is highlighted as part of the industry's commitment to promote female leadership in biotech.